CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-a-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, announced the initiation of DOMMINO-1, a pivotal Phase 2 clinical trial evaluating...
ProductLife Group (PLG), a global provider of consulting and outsourcing services for the life sciences industry, has appointed Dr. James Burt as Chief Executive Officer. Dr. Burt brings more than 20 years of international leadership experience...
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh...
Oryon Cell Therapies a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, announced it has emerged from stealth and has closed a new $21...
The labor dispute at Samsung Biologics, the world’s leading contract development and manufacturing organization (CDMO), has reached a critical juncture. Representing approximately 75% of the company's workforce, the Samsung Biologics Labor Union...
Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of prostate cancer, announced the appointment of Michael Rossi to its Board of Directors. Mr. Rossi...
Johnson & Johnson a worldwide leader in multiple myeloma therapies, announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of...
ulrich medical USA is pleased to announce the appointment of Alissa Calaway, RN, MSN, as Director of U.S. Clinical Affairs. Alongside this leadership appointment, the company is launching a U.S.-based Clinical Research Program designed to generate...
-Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced the final close of its oversubscribed $105 million Series C funding. The round...
Eton Pharmaceuticals, Inc an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre...
US-Rx Care, the nation's first fiduciary pharmacy risk manager and an industry leader since 2007, is issuing an urgent strategic call-out to employers: the Pharmacy Benefit Manager (PBM) industry has reached a point of no return. After years of...
renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy. These data are being presented as a late-breaking oral abstract at the 2026 American...
3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, announced the appointment of Rebeca Villarreal-Barragan, MBA, as head of clinical operations. In this role, Ms....
and enrollment processes, it accelerates study execution and delivers results more efficiently. Regimen I Regimen I (NUZ-001) includes a randomised, placebo-controlled treatment (RCT) phase followed by an active treatment extension (ATE) phase,...
Matricelf Ltd. a biotechnology company developing autologous engineered tissue therapies, today announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and...
Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more...
ARUP Laboratories, a leader in diagnostic medicine and the largest nonprofit reference laboratory in the U.S., announced the launch of a new Innovation Central Laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other...
CollPlant a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print...
Bruker Corporation announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional...
to receive one more cycle of 67Cu-SAR-bisPSMA, and no disease was observed on PSMA PET following the second dose (Figure 1). This participant exhibited mild (Grade 1) related AEs, including altered taste, dry eyes, eye pain, fatigue and salivary...